Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics

Abstract

Background

The recently growing interest in targeted alpha-therapy (TAT) calls for improvement of the labelling chemistry of the corresponding radionuclides. ²¹³Bi^III is a short-lived alpha emitter which emits only one alpha particle in its decay chain. Hence, it might be safer in application than other respective nuclides, such as ²²³Ra or ²²⁵Ac, because no alpha-emitting daughters are released upon recoil. We investigated cyclen derivatives with phosphorus-containing pendant arms regarding their suitability for ²¹³Bi labelling.

Results

The concentration dependency of ²¹³Bi labelling at 25 °C and 95 °C was determined for DOTP, DOTP^H, DOTP^Et, and DOTPI, as well as for DOTA and CHX-A"-DTPA for comparison. The labelling efficiency of the phosphorus-containing ligands was at least comparable to CHX-A"-DTPA and exceeded that of DOTA. DOTP was most efficient, requiring chelator concentrations for labelling which were approx. two orders of magnitude lower than those required for CHX-A"-DTPA, both at 25 °C and 95 °C. The ²¹³Bi complexes of phosphorus ligands furthermore showed a higher stability against demetallation (> 96% of intact complex after 120-min incubation in plasma were found for DOTP, DOTP^H, and DOTP^Et, compared to 85% for DOTA and 76% for CHX-A"-DTPA).

Conclusion

Cyclen derivatives bearing four N-methylenephosphonic or -phosphinic acid substituents, e.g., DOTP, are capable of complexing the alpha-emitting radionuclide ²¹³Bi^III with higher efficiency and in-vitro stability than the current gold standards DOTA and CHX-A"-DTPA.

https://ift.tt/2AQMiuZ